PubMed Health⌕ Search

Biomedical subjects

Y Audigier

Publications and source records attributed to Y Audigier.

45 records · Page 3Linked to original sources

Comparative study of analgesia induced by N VAL5- and Pro5-enkephalin analogs.

We have compared the analgesic potency of N-Val5 analogs and Pro5 derivatives in order to identify the mechanism of the unusually strong antinociceptive activity induced by Pro5 enkephalin analogs. Whereas N-Val5 and Pro5 compounds are equiactive in in vitro assays, N-Val5 derivatives are considerably less active analgesics than Pro5 analogs. Since N-Val is the homolog of Pro with an opened pyrrolidine ring, these data show that the cyclic structure of Pro participates in the strong in vivo activity of Pro5 analogs without altering the binding to the opiate receptor.

Analgesia↗

Structure-activity relationships of enkephalin analogs at opiate and enkephalin receptors: correlation with analgesia.

We have investigated the influence of physico-chemical parameters (chemical structure and lipophilicity), biochemical properties (catabolism, affinity for 3H-etorphine binding sites and 3H-(D-Ala)2-Leu5-enkephalin amide binding sites) and biological activity in isolated organs (guinea-pig ileum and mouse vas deferens) on the regulation of analgesia induced after intracerebroventricular injection of various enkephalin analogs. The selectivity of these metabolically stable analogs for micro- and beta-receptors, present in guinea-pig ileum and mouse vas deferens respectively, depends on the C-terminal amino acid and also on the nature of the second D-amino-acid. A strong correlation exists between activity in guinea-pig ileum and affinity for 3H-etorphine binding sites suggesting that these sites in rat brain have properties identical to those of micro-receptors characterized in guinea-pig ileum. Similarly, the affinity for 3H-(D-Ala)2-Leu5-enkephalin amide binding sites in mouse brain is correlated to the activity in mouse vas deferens and suggests that central beta-receptors are not different from peripheral beta-receptors. If we consider morphine-like drugs and enkephalin analogs containing the same C-terminal amino acid as the enkephalins, there is a good correlation between activity on micro-receptors (affinity for 3H-etorphine binding sites and activity in guinea-pig ileum) and the antinociceptive activity. These results support the hypothesis that micro-receptors are strongly involved in the analgesic effect. However, when proline is the C-terminal amino acid, the antinociceptive activity was enhanced without any concomitant increase in the affinity. This activity enhancement was the same for each analog and a similar correlation (identical to what was found with other opioid peptides and opiates) could still be established. The reason for such a potentiation of the activity remains to be elucidated.

Amino Acid Sequence↗

[Binding sites for 3H-Leu-enkephalin in rat straitum].

The binding of 3H-Leu-Enkephalin to a particulate fraction from Rat striatum has been investigated in the presence of 20 mum bacitracin which prevents its hydrolysis. After deduction of a low-affinity, "non-saturable" component, the saturation kinetics at equilibrium provide evidence for two distinct saturable sites. The first exhibits Michaelis kinetics with a Kd value of 2.7 +/- 0.1 nM; both morphine and naloxone compete with the binding of 3H-Leu-Enkephalin on this site but not on the second one. The marked decrease in binding of 3H-Leu-Enkephalin observed in the presence of high concentration of sodium ions indicates that these two pentapeptides have the same properties as morphinomimetic analgesics. Taken together, these data indicate that the first site is identical to the "opiate receptor", while the nature of the second saturable site remains to be established.

Analgesics↗

Characterization of [3H]-etorphine binding in guinea-pig striatum after blockade of mu and delta sites.

The guinea-pig striatum contains an apparent homogenous population of [3H]-etorphine high affinity sites (KD = 0.56 +/- 0.12 nM; Bmax = 267 +/- 47 fmoles/mg protein). The specific binding is completely abolished by 5 microM (D-Ala2, D-Leu5) enkephalin whereas an important residual binding is still present after the blockade of mu and delta sites. The binding properties of these residual sites are very similar to those of the benzomorphan sites characterized in rat brain and spinal cord. From the different binding properties of kappa and benzomorphan sites, the subdivision into kappa1 (kappa sites) and kappa2 (benzomorphan sites) is discussed.

Animals↗

Differential interaction of opiates to multiple "kappa" binding sites in the guinea-pig lumbo-sacral spinal cord.

Binding characteristics of [3H]-etorphine and [3H]-ethylketocyclazocine are different in the lumbo-sacral spinal cord of guinea-pig. [3H]-etorphine binds to a single class of high affinity sites whereas [3H]-ethylketocyclazocine interacts with two components, a high affinity and a low affinity components. In the presence of 5 microM (D-Ala2, D-Leu5) enkephalin (DAL), the total high affinity sites can be resolved in two classes of sites, DAL sensitive sites (DALs sites) and DAL insensitive sites (DALI sites). In these conditions, [3H]-etorphine binding is completely abolished, and the binding capacity and properties of [3H]-etorphine correspond to the DALs sites. Pharmacological investigations indicated that DALI sites represent the kappa sites, whereas DALs sites closely correspond to benzomorphan sites described in rat brain and spinal cord. From these results, a new subclassification of "kappa" sites is proposed.

Analgesics, Opioid↗